福氏与宋内氏志贺氏菌二价抗原杂交株的组建

我们将标记Tn5的宋内氏菌Ⅰ相大质粒经诱动质粒R386诱动转移到福氏2aT_(32)菌苗株内,组建了二价抗原杂交株Fs-18。该株既表达福氏2a型(Ⅱ)、群(3、4)抗原,又表达宋内氏菌Ⅰ相抗原。刚果红吸收试验、组织培养物HeLa细胞侵入试验以及Sereny试验均证明Fs-18株无毒。用Fs-18株免疫小鼠可对福氏2a和宋内氏毒株攻击提供双重保护作用。     

Epidemic Reiter's syndrome following an outbreak of shigellosis

We prospectively studied the occurrence of Reiter's syndrome (RS) or reactive arthritis (ReA) in 205 of 349 cruise-ship passengers who attended a buffet ashore and developed Shigella flexneri 2a enteritis. Five passengers probably had RS/ReA and 16 were possible or doubtful cases of RS/ReA. HLA-B27 was identified in 4 of 5 probable RS cases, but was not present in any of the 16 possible or doubtful cases nor in any of 20 passengers (controls) without any symptoms of RS/ReA. There was no statistically significant difference in the frequency of B7-Creg antigens in persons with possible or doubtful RS/ReA (9/16) compared to controls (8/20).currently with Center for Vaccine Development University of Maryland, Baltimore, MD.Corresponding author.     

Tyrosine kinases,drugs, and Shigella flexneri dissemination

Shigella flexneri is an enteropathogenic bacterium responsible for approximately 100 million cases of severe dysentery each year. S. flexneri colonization of the human colonic epithelium is supported by direct spread from cell to cell, which relies on actin-based motility. We have recently uncovered that, in intestinal epithelial cells, S. flexneri actin-based motility is regulated by the Bruton’s tyrosine kinase (Btk). Consequently, treatment with Ibrutinib, a specific Btk inhibitor currently used in the treatment of B-cell malignancies, effectively impaired S. flexneri spread from cell to cell. Thus, therapeutic intervention capitalizing on drugs interfering with host factors supporting the infection process may represent an effective alternative to treatments with antimicrobial compounds.     

Immunoproteome analysis of soluble and membrane proteins of Shigella flexneri 2457T

INTRODUCTION Shigellosis is a public health concern in developing countries, particularly for young children who make up 69% of all cases. The majority of shigellosis cases in the Asian, African and Central American regions are caused by Shigella flexneri…     

福氏志贺菌中质粒介导喹诺酮类耐药qnr基因的检测

目的 了解福氏志贺菌中qnr基因的分布.方法 采用PCR法检测26株福氏志贺菌的qnr基因并对阳性扩增产物进行测序分析,采用琼脂稀释法测定qnr基因阳性菌株对多种抗菌药物的敏感性,采用随机引物PCR法(ERIC-PCR)进行qnr基因阳性菌株同源性检测.结果 26株福氏志贺菌中,qnrAl、qnrS1和qnrS2基因的阳性率分别为30.8%、11.5%和3.8%;qnr基因阳性菌株对氯霉素、奈啶酸耐药.对诺氟沙星、哌拉西林耐药或中介;部分菌株对头孢唑啉、阿米卡星、第二、三代头孢菌素耐药.ERIC-PCR电泳图谱型显示.2株qnrAl基因阳性菌株属于同一谱型.结论 福氏志贺菌中存在qnr基因阳性菌株,部分菌株间存在克隆传播现象,临床应加强检测和监测.     

北京市海淀区1999～2005年细菌性痢疾流行特征

目的了解海淀区7年来细菌性痢疾发病规律、流行特征，为2008年北京奥运会传染病保障工作提供基础本底资料，为细菌性痢疾防治策略提供科学依据。方法根据海淀区1999～2005年细菌性痢疾传染病疫情报告作描述性分析，对2004年60株志贺菌进行血清学分型。结果1999～2005年细菌性痢疾发病率波动在134．05／10万～353．98／10万之间，年均发病率在234．02／10万，总体呈下降趋势；发病以5～9月份为主，发病最高峰在每年的8月份；0～4岁组婴幼儿发病率最高达93．8．15／10万；不同职业发病数前三位是学生、干部职员、散居儿童。志贺菌60株分型，福氏志贺菌37株占61．67％，宋内氏志贺菌23株占38．33％，福氏37株以福氏4为主（15株，占40．52％）。结论海淀区近7年来细菌性痢疾发病率呈下降趋势，但发病率远远高于全国平均水平，始终占据法定传染病发病首位。夏秋季为细菌性痢疾发病高峰期；0～4岁组、学生、干部职员为重点防治对象。以福氏志贺菌、宋内氏志贺菌两型为流行株。     

Extended-spectrum beta-lactamases in Shigella flexneri from Argentina: first report of TOHO-1 outside Japan

A 9-year nation wide survey of the presence of extended-spectrum β-lactamases (ESBLs) in Shigella flexneri is described. Ten of 9033 (0.1%) isolates produced ESBLs, which were characterized by isoelectric focusing, PCR and DNA sequencing. These were CTX-M-2 (five isolates), TOHO-1 (one isolate), SHV-2 (two isolates) and PER-2 (two isolates, the first report in S. flexneri world wide). The emergence of each ESBL type in S. flexneri was not restricted to a particular region of Argentina. TOHO-1 showed a more basic isoelectric point (8.4) than that previously found (7.8) and its encoding gene (bla_TOHO-1a) harboured a silent change, G825A, relative to the reported bla_TOHO-1. All the ESBL-encoding genes were transferred to Escherichia coli by conjugation. PFGE analysis indicated that the 10 ESBL-producing S. flexneri isolates were subtypes of a unique clone.     

福氏志贺菌毒力蛋白IpaC的表达、纯化及免疫活性鉴定

目的表达、纯化福氏志贺菌毒力蛋白IpaC并对其免疫活性进行鉴定。方法将含有ipaC基因的pET32a．ipaC表达质粒载体转入大肠杆菌BL21（kDE3）中表达，表达产物进行SDS—PAGE鉴定，并采用QIA expressionist^TM蛋白纯化系统纯化IpaC蛋白；用纯化的蛋白免疫动物获得抗血清，Western-blot检测抗原的免疫活性。结果诱导后的表达产物经SDS—PAGE发现有一相对分子量约为63000的条带，其含量约占总蛋白量的11％，对融合蛋白进行纯化纯度可达90％以上，抗His的抗体Western-blot分析，发现特异性区带出现在63000u处，证明该蛋白是所要表达的融合蛋白，制备的免疫血清可与Ipac发生特异免疫反应。结论pET32a-ipaC重组表达质粒转入大肠杆菌后，可稳定、高效地表达毒力蛋白IpaC，且纯化后的蛋白具有免疫活性。     

慢性菌痢临床分析及随访

本文报道1958～1984年经细菌学证实为慢性菌痢86例的临床分析及30例的随访。86例中以福氏痢疾杆菌引起者占91.4%。随访结果大便培养均未发现痢疾杆菌,细菌学治愈率达100％,治后偶有排脓血便者仅3例。乙状结肠镜检大多无异常发现,有溃疡1—2个者仅2例,未发现恶性变及典型非特异性溃疡性结肠炎改变。     

411例小儿急性腹泻细菌性病原学和临床探讨

本文对1983年6月—10月间411例小儿急性腹泻门诊病例细菌性病原学和临床进行了观察,共检出致病菌132株,总检出率为31.1%,以志贺氏菌检出率最高,空肠弯曲菌次之,检出致病性大肠杆菌EPEC14株,测不耐热肠毒素全部阴性。复方新诺明对福氏痢疾杆菌的敏感度已由70年代的97%下降到7.89%,是一个值得重视的问题。